The Full Wiki

More info on Dopamine agonist

Dopamine agonist: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

A dopamine agonist is a compound that activates dopamine receptors in the absence of the dopamine ligand. Dopamine agonists activate signaling pathways through the dopamine receptor and trimeric G-proteins, ultimately leading to changes in gene transcription.



Some medical drugs act as dopamine agonists; they are typically used for treating Parkinson's disease and certain pituitary tumors (prolactinoma), and may be useful for restless legs syndrome (RLS). Both Requip (Ropinirole) and Mirapex (Pramipexole) are FDA-approved for the treatment of RLS. There is also an ongoing clinical trial to test the effectiveness of Requip (ropinirole), a dopamine agonist, in reversing the symptoms of SSRI-induced sexual dysfunction and Post-SSRI sexual dysfunction (PSSD).[1]


Some of the common side effects of dopamine agonists include:[2][3]


Examples of dopamine agonists include:

Some, such as fenoldopam, are selective for dopamine receptor D1.[5]

See also


  1. ^ NCT00334048 - "Treating Sexual Dysfunction From SSRI Medication: a Study Comparing Requip CR to Placebo"
  2. ^ "MedlinePlus Drug Information: Pramipexole (Systemic)". United States National Library of Medicine. Retrieved 2006-09-27.  
  3. ^ Boyd, Alan (1995). "Bromocriptine and psychosis: A literature review". Psychiatric Quarterly 66 (1): 87–95. doi:10.1007/BF02238717. Retrieved 2008-09-06.  
  4. ^ FDA Announces Voluntary Withdrawal of Pergolide Products
  5. ^ Ng SS, Pang CC (March 2000). "In vivo venodilator action of fenoldopam, a dopamine D(1)-receptor agonist". Br. J. Pharmacol. 129 (5): 853–8. doi:10.1038/sj.bjp.0703119. PMID 10696081. PMC 1571905.  

6. Avanzi M, Uber E, Bonfa F. Pathological gambling in two patients on dopamine replacement therapy for Parkinson’s disease. Neurol Sci 2004; 25:98–101[Medline]

External links



Got something to say? Make a comment.
Your name
Your email address